We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- obesity/erectile dysfunction

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: scaram(o)uche8/21/2017 3:08:41 PM
   of 435
Review of various commercial development efforts, packed with surface info. Good starting point.

Love to see the totality of data behind this..... "The cell-based ligand screening involved approximately 80 phytocannabinoids, with the initial screen resulting in the identification of several hits that were effective in preventing the activation of the cells by transforming growth factor-beta, or TGF-beta."

Something like this pops out, and you wonder if cognitive disorder is just a shot in the dark or ????. In context, one might go.... "yeah, neuropathic pain, but.... huh?" Different context?

"Cleveland Clinic spinout Neurotherapia Inc. is seeking to move NTRX-07, a CB2 agonist, into the clinic to treat cognitive disorder and neuropathic pain"
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext